2023 World Conference on Lung Cancer (Posters)-P1.08. Impact of KRASG12D Subtype and Concurrent Pathogenic Mutations on Advanced Non-small Cell Lung Cancer Outcomes

P1.08. Impact of KRASG12D Subtype and Concurrent Pathogenic Mutations on Advanced Non-small Cell Lung Cancer Outcomes - PDF(Slides)

Back to course

Pdf Summary

This study aimed to analyze the clinicopathological and genomic characteristics of Latin American patients with KRAS-mutated advanced non-small cell lung cancer (NSCLC) and their impact on clinical outcomes. KRAS mutations are a significant driver of lung adenocarcinoma, present in 10-40% of patients, and have heterogeneous clinical outcomes. The study found that the KRASG12D subtype was associated with favorable outcomes, likely due to its infrequent concurrence with STK11 and its association with EGFR commutation. On the other hand, worse survival outcomes were noted in the KRASnonG12D group, especially after treatment regimens without immunotherapy. The study highlights that KRAS-mutated NSCLC is not a homogeneous disease and emphasizes the prognostic impact of diverse molecular profiles. Access to immunotherapy in Latin America needs to be improved to benefit patients with KRAS-mutated NSCLC. The study provides insights into the structural representation and frequency of KRAS mutations, smoking history according to packs per year in different KRAS mutation groups, clinical characteristics and comutations of KRAS-mutated NSCLC patients, assessment of PD-L1 expression according to the G12D mutation, association probability of KRAS with other driver genes, and type of responses to all treatments according to KRAS G12D mutation. Ultimately, the study contributes to the understanding of the impact of KRAS mutations on advanced NSCLC outcomes and the need for personalized treatment approaches based on molecular profiles.

Asset Subtitle

Norma Hernandez-Pedro

Meta Tag

Speaker Norma Hernandez-Pedro

Topic Tumor Biology: Translational Biology - Drug Resistance

Keywords

KRAS-mutated NSCLC

Latin American patients

clinicopathological characteristics

genomic characteristics

clinical outcomes

KRAS mutations

lung adenocarcinoma

immunotherapy

molecular profiles

personalized treatment